Company / Operating Income
Aligos Therapeutics, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$88.0M
FY2025
5-year range
-$128.3M / -$88.0M
FY2021-FY2025
Trend
+1.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has increased for 3 consecutive years, from -$128M in FY2022 to -$88M in FY2025.
Based on SEC 10-K filings.
-$88M in FY2025.
Improved from -$98M to -$88M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Aligos Therapeutics, Inc.'s operating income has grown for 3 consecutive years.
- In FY2025, operating income increased 1.3% year-over-year.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$88.0M | +1.3% |
| FY2024 | -$89.2M | +8.6% |
| FY2023 | -$97.6M | +24.0% |
| FY2022 | -$128.3M | -31.2% |
| FY2021 | -$97.8M | -81.0% |
| FY2020 | -$54.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026